Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04401020
Recruitment Status : Recruiting
First Posted : May 26, 2020
Last Update Posted : July 26, 2022
Information provided by (Responsible Party):

Brief Summary:

Primary Objective:

To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D)

Secondary Objectives:

  • To characterize the safety profile of SAR442257
  • To characterize the pharmacokinetics (PK) profile of SAR442257
  • To evaluate the potential immunogenicity of SAR442257
  • To assess preliminary evidence of antitumor activity

Condition or disease Intervention/treatment Phase
Neoplasm Malignant Drug: SAR442257 Phase 1

Detailed Description:
Study duration per participant is 2 months to estimated 16 months. Cycle lengths in this study are 27 days in Cycle 1 and 28 days for subsequent cycles as determined by totality of data collected thus far including PK/Pharmacodynamics (PD), safety and preliminary efficacy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 57 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, First-in-human, Single Agent, Dose Escalation Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442257 in Patients With Relapsed and Refractory Multiple Myeloma and Relapsed and Refractory Non-Hodgkin Lymphoma
Actual Study Start Date : July 24, 2020
Estimated Primary Completion Date : January 2024
Estimated Study Completion Date : June 5, 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Dose escalation
SAR442257 will be given intravenously with lead-in doses (LID) in the first-week, followed by twice weekly until week 4 (Cycle 1) and twice weekly for each subsequent cycle(s).
Drug: SAR442257
Pharmaceutical form: Sterile lyophilized powder for reconstitution Route of administration: Intravenous infusion

Primary Outcome Measures :
  1. Determine maximum tolerated dose (MTD) [ Time Frame: Baseline to estimated 4 weeks ]
    MTD: defined as the highest dose level (DL) with highest probability of Investigational Medicinal Product (IMP)-related dose limiting toxicity (DLT) rate within the target range (16 to 33%) among dose levels with less than 0.25 probability of DLT rate above target (>33%)

  2. Determine recommended Phase 2 dose (RP2D) [ Time Frame: Baseline to estimated 4 months ]
    RP2D: defined as the dose selected for the further single agent testing in the future study

Secondary Outcome Measures :
  1. Number of participants with AEs/SAEs/AESI [ Time Frame: Baseline to 30 days after end of treatment ]
    Incidence of treatment-emergent adverse events (AEs)/serious adverse events (SAEs)/ adverse events of special interest (AESIs)

  2. Assessment of pharmacokinetic (PK) parameter: Cmax [ Time Frame: through study completion (estimated 16 months) ]
    Maximum concentration observed (Cmax)

  3. Assessment of PK parameter: Ctrough [ Time Frame: through study completion (estimated 16 months) ]
    Concentration observed just before treatment administration during repeated dosing (Ctrough)

  4. Assessment of PK parameter: AUC0-τ [ Time Frame: up to 5 weeks ]
    Area under the concentration versus time curve during a dosing interval (T) (AUC0-τ)

  5. Incidence of anti-drug antibody (ADA) [ Time Frame: Baseline to 30 days after end of treatment ]
    Incidence of (ADA) against SAR442257

  6. Overall response rate for RRMM [ Time Frame: Baseline to 6 months ]
    Overall response rate will be assessed using the International Myeloma Working Group (IMWG) 2016 criteria for patients with RRMM

  7. Overall response rate for RR-NHL [ Time Frame: Baseline to 6 months ]
    Overall response rate will be assessed using the Response evaluation criteria in lymphoma (RECIL) 2017 criteria for patients with RR-NHL

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria :

Participant must be at least 18 years of age or of the country's legal age of majority if the legal age is >18 years old, at the time of signing the informed consent.

Life expectancy of at least 12 weeks. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

RRMM patients:

must have received at least 3 prior lines of therapy including proteasome inhibitor (PI), immunomodulatory agent (IMiD), and anti-CD38 mAb; and must have received their last dose of prior anti-CD38 therapy within 12 months prior to the first dose of SAR442257; and must be refractory to anti-CD38 antibody (eg, daratumumab or isatuximab), characterized by progression within 60 days of the last dose of anti-CD38, regardless of which line it was given; and must be either relapsed or refractory to all established therapies with known clinical benefit in RRMM where approved and available, or are intolerant to those established therapies; based upon investigator's clinical judgement.

and must not be candidates for regimens known to provide clinical benefit based upon investigator's clinical judgement.

Patients with RRMM must have measurable disease as per the following:

  • Serum M protein ≥0.5 g/dL (≥5 g/L), or
  • Urine M protein ≥200 mg/24 hours, or
  • Serum free light chain (FLC) assay: involved FLC assay ≥10 mg/dL and an abnormal serum FLC ratio (<0.26 or >1.65).

Patients with RR-NHL must be relapsed or refractory to all established therapies with known clinical benefit where approved and available, or are intolerant to those established therapies; based upon investigator's clinical judgement.

Patients with RR-NHL must have measurable disease of at least one lesion ≥1.5 cm as documented by computed tomography (CT) scan, including the following subtype of disease:

  • Diffuse large B-cell lymphoma (DLBCL).
  • transformed follicular lymphoma (tFL),
  • follicular lymphoma (FL),
  • mantle cell lymphoma (MCL),
  • marginal zone lymphoma (MZL),
  • lymphoplasmacytic lymphoma,
  • small lymphocytic lymphoma (SLL). Patients with RR-NHL subtype T cell lymphoma (TCL): histopathologically confirmed mycosis fungoides or Sézary syndrome (cutaneous T cell lymphoma [CTCL] stage IIB or greater according to the European Organization for Research and Treatment of Cancer/International Society for Cutaneous Lymphomas [EORTC-ISCL] consensus classification) at study entry with progressive, persistent, or recurrent disease who have no available remaining standard therapeutic options (ie, refractory) as determined by the Investigator.

Patients with lymphoma must have availability of lymphoma tissue for biomarker testing: either archived tissue or a fresh biopsy as a part of screening. On-treatment biopsy (Cycle 2 or beyond) is also expected if disease location is in a superficial lymph node. For post-CAR-T patients a fresh LN biopsy is expected if in a superficial node. For these patients tissue materials should be made available for analysis during the study. Excisional biopsy or resected tissue is required if clinically feasible; otherwise, core needle biopsy is acceptable. Fine needle aspirates are not acceptable.

Patients with lymphoma must have a ≥50% left ventricular ejection fraction (LVEF) and no pericardial effusion, as measured by echocardiogram (ECHO).

Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria:

Diagnosed or treated for another malignancy within 3 years prior to enrollment, except for basal cell carcinoma or squamous cell carcinoma of the skin, an in-situ malignancy, superficial bladder carcinoma or low risk prostate cancer.

Amyloidosis, leukemic manifestations of lymphoma, chronic lymphocytic leukemia and prolymphocytic leukemia.

Known central nervous system (CNS) involvement by myeloma, lymphoma or other CNS disease such as neurodegenerative condition or CNS movement disorder.

Has congestive heart failure (New York Heart Association) Grade ≥II; cardiomyopathy, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant arrhythmia requiring therapy including anticoagulants, or clinically significant uncontrolled hypertension, QT interval corrected by the Fridericia method >480 msec (Grade ≥2). Acute myocardial infarction within 6 months before start of study treatment.

Has active autoimmune disease including autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel syndrome, pneumonitis or any chronic condition requiring a higher corticosteroid systemic equivalent than prednisone 10 mg daily.

Clinically-not controlled chronic or ongoing infectious disease requiring treatment at the time of first dose or within the 14 days before first dose.

Active hepatitis A, B, and C as defined below: active hepatitis A (defined as positive IgM), active hepatitis B (defined as either positive hepatitis B surface antigen or positive hepatitis B viral DNA test above the lower limit of detection of the assay, and hepatitis B core antibodies), or C infection (defined as a known positive hepatitis C antibody result and known quantitative hepatitis C [HCV] ribonucleic acid [RNA] results greater than the lower limits of detection of the assay).

Known positivity for Human Immunodeficiency Virus (HIV). Unresolved toxicities from prior anticancer therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade 1 or to levels dictated in the eligibility criteria with the exception of Grade 1 peripheral neuropathy, alopecia or toxicities from prior anticancer therapy that are considered irreversible (defined as having been present and stable for >4 weeks) which may be allowed if they are not otherwise described in the exclusion criteria.

Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04401020

Layout table for location contacts
Contact: Trial Transparency email recommended (Toll free number for US & Canada) 800-633-1610 ext option 6

Layout table for location information
United States, California
Investigational Site Number :8400001 Recruiting
Duarte, California, United States, 91010
United States, Florida
Investigational Site Number :8400005 Recruiting
Miami, Florida, United States, 33136
United States, Minnesota
Investigational Site Number :8400003 Recruiting
Rochester, Minnesota, United States, 55905
Investigational Site Number :2030003 Recruiting
Brno, Czechia, 62500
Investigational Site Number :2030001 Recruiting
Ostrava - Poruba, Czechia, 70852
Investigational Site Number :2030002 Recruiting
Praha 2, Czechia, 12808
Korea, Republic of
Investigational Site Number :4100001 Recruiting
Seoul, Seoul-teukbyeolsi, Korea, Republic of, 03080
Investigational Site Number :4100002 Recruiting
Seoul, Seoul-teukbyeolsi, Korea, Republic of, 06351
Investigational Site Number :5780001 Recruiting
Oslo, Norway, 0440
Investigational Site Number :5780101 Recruiting
Oslo, Norway, 0450
Investigational Site Number :7240003 Recruiting
Badalona, Catalunya [Cataluña], Spain, 08916
Investigational Site Number :7240001 Recruiting
Pamplona, Navarra, Spain, 31008
Investigational Site Number :7240004 Recruiting
Valencia, Spain, 46026
Sponsors and Collaborators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Sanofi Identifier: NCT04401020    
Other Study ID Numbers: TED16364
2019-003390-26 ( EudraCT Number )
U1111-1244-2511 ( Other Identifier: UTN )
First Posted: May 26, 2020    Key Record Dates
Last Update Posted: July 26, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at:

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms